Tsakiroglou, Anna-Maria Astley, Susan Dave, Manàs Fergie, Martin Harkness, Elaine Rosenberg, Adeline Sperrin, Matthew West, Catharine Byers, Richard Linton, Kim
...
Published in
Cancer immunology, immunotherapy : CII
Follicular lymphoma (FL) prognosis is influenced by the composition of the tumour microenvironment. We tested an automated approach to quantitatively assess the phenotypic and spatial immune infiltrate diversity as a prognostic biomarker for FL patients. Diagnostic biopsies were collected from 127 FL patients initially treated with rituximab-based ...
Chen, Hui-Ming Sun, Linus Pan, Ping-Ying Wang, Lu-Hai Chen, Shu-Hsia
Published in
Cancer immunology, immunotherapy : CII
Specific extracts of selected vegetables (SV) have been shown to benefit the survival of stage IIIb/IV non-small cell lung cancer patients in phase I/II studies and is currently in a phase III trial. However, the underlying mechanism of SV-mediated antitumor immune responses has not been elucidated. Our results indicate that SV modulated the NK and...
Tasaki, Mamoru Yamashita, Midori Arai, Yukinori Nakamura, Takafumi Nakao, Shinsuke
Published in
Cancer immunology, immunotherapy : CII
Immune checkpoint inhibitors against PD-1, PD-L1 and CTLA-4 have altered the treatment paradigm for various types of cancers in the past decade. However, they offer clinical benefits to only a subset of patients. Evaluation and identification of an appropriate therapeutic approach to improve intratumoral immune status are needed for better treatmen...
Deronic, Adnan Nilsson, Anneli Thagesson, Mia Werchau, Doreen Enell Smith, Karin Ellmark, Peter
Published in
Cancer immunology, immunotherapy : CII
Non-responders to checkpoint inhibitors generally have low tumor T cell infiltration and could benefit from immunotherapy that activates dendritic cells, with priming of tumor-reactive T cells as a result. Such therapies may be augmented by providing tumor antigen in the form of cancer vaccines. Our aim was to study the effects of mitazalimab (ADC-...
Rodin, William Sundström, Patrik Ahlmanner, Filip Szeponik, Louis Zajt, Kamil Kajetan Wettergren, Yvonne Bexe Lindskog, Elinor Quiding Järbrink, Marianne
Published in
Cancer immunology, immunotherapy : CII
Mucosal-associated invariant T (MAIT) cells are unconventional T cells recognizing microbial metabolites, presented by the invariant MR1 protein. Upon activation, MAIT cells rapidly secrete cytokines and exert cytotoxic functions, and may thus be highly relevant also in tumor immunity. MAIT cells accumulate in colon tumors, but in contrast to other...
Hansen, Kyle Kumar, Sandeep Logronio, Kathryn Whelan, Sarah Qurashi, Samir Cheng, Hsin-Yuan Drake, Andrew Tang, Margaret Wall, Patrick Bernados, David
...
Published in
Cancer immunology, immunotherapy : CII
Immune checkpoint inhibitors (ICIs) have emerged as promising therapies for the treatment of cancer. However, existing ICIs, namely PD-(L)1 and CTLA-4 inhibitors, generate durable responses only in a subset of patients. TIGIT is a co-inhibitory receptor and member of the DNAM-1 family of immune modulating proteins. We evaluated the prevalence of TI...
Kanie, Keitaro Iguchi, Genzo Bando, Hironori Urai, Shin Shichi, Hiroki Fujita, Yasunori Matsumoto, Ryusaku Suda, Kentaro Yamamoto, Masaaki Fukuoka, Hidenori
...
Published in
Cancer immunology, immunotherapy : CII
Immune checkpoint inhibitors (ICIs) as a cancer immunotherapy have emerged as a treatment for multiple advanced cancer types. Because of enhanced immune responses, immune-related adverse events (irAEs), including endocrinopathies such as hypophysitis, have been associated with the use of ICIs. Most underlying mechanisms of ICI-related hypophysitis ...
Hu, Hai-Jun Liang, Xiu Li, Hai-Lang Wang, Huai-Yuan Gu, Jin-Fa Sun, Lan-Ying Xiao, Jing Hu, Jin-Qing Ni, Ai-Min Liu, Xin-Yuan
...
Published in
Cancer immunology, immunotherapy : CII
Although the recent treatment in melanoma through the use of anti-PD-1 immunotherapy is successful, the efficacy of this approach remains to be improved. Here, we explore the feasibility of combination strategy with the armed oncolytic adenovirus ZD55-IL-24 and PD-1 blockade. We find that combination therapy with localized ZD55-IL-24 and systemic P...
Salewski, Inken Kuntoff, Steffen Kuemmel, Andreas Feldtmann, Rico Felix, Stephan B Henze, Larissa Junghanss, Christian Maletzki, Claudia
Published in
Cancer immunology, immunotherapy : CII
Mlh1-knock-out-driven mismatch-repair-deficient (dMMR) tumors can be targeted immunologically. By applying therapeutic tumor vaccination, tumor growth is delayed but escape mechanisms evolve, including upregulation of immune-checkpoint molecules (LAG-3, PD-L1). To counteract immune escape, we investigated the therapeutic activity of a combined tumo...
Dahariya, Swati Raghuwanshi, Sanjeev Sangeeth, Anjali Malleswarapu, Mahesh Kandi, Ravinder Gutti, Ravi Kumar
Published in
Cancer immunology, immunotherapy : CII
Acute megakaryocytic leukemia (AMKL) is one of the rarest sub-types of acute myeloid leukemia (AML). AMKL is characterized by high proliferation of megakaryoblasts and myelofibrosis of bone marrow, this disease is also associated with poor prognosis. Previous analyses have reported that the human megakaryoblastic cells can be differentiated into ce...
